Advertisement

NLS SAGA Diagnostics

Agreement - November 8, 2021

SAGA Diagnostics and AstraZeneca enter agreement

SAGA Diagnostics has entered into an assay development agreement with AstraZeneca. SAGA Diagnostics will in the course of this agreement develop SAGAsafe dPCR assays towards undisclosed methylated targets for analyses of tissue samples and liquid biopsies. “We have chosen to partner with SAGA because of the ultrasensitive performance of the SAGAsafe technology and possibility to […]

Financing - June 29, 2021

SAGA Diagnostics raises 106 million SEK

SAGA Diagnostics has raised SEK 106 million (€10.5 million) in a Series A2 financing from both existing and new investors. The Series A2 round was led by Segulah Medical Acceleration and the Sciety investment syndicate with strong support from existing shareholders such as Hadean Ventures. “We are delighted to complete this oversubscribed financing round with […]

Collaboration - June 21, 2021

SAGA Diagnostics expands research collaboration

The company has announced an expanded research collaboration with Professor Charles Swanton, at the University College London (UCL) Cancer Institute. Last year, SAGA and UCL entered into a research collaboration on a limited number of patients. With the newly signed agreement, SAGA will utilize its SAGAsafe assays for detection of a panel of mutations in […]

Pharma Diagnostics - June 16, 2021

SAGA Diagnostics achieves ISO 17025 accreditation

SAGA Diagnostics has been accredited to the ISO 17025 standard for its mutation detection laboratory services designed to improve cancer diagnosis, monitoring, and treatment outcomes. Granted by SWEDAC, the Swedish Board for Accreditation and Conformity Assessment, ISO 17025 is an international quality management standard used to assess the competency of analytical laboratories. A milestone “The […]

Agreement - January 29, 2020

SAGA Diagnostics extends collaboration with Servier

SAGA Diagnostics has entered service agreements with the international pharmaceutical company Servier, based in Paris, France. “These deals exemplify the increased demand we are experiencing for our offerings of ultrasensitive cancer analysis services and analysis kits. We are excited to be working with Servier, who continues to choose us for important translational oncology projects,” says […]

Careers article - November 14, 2017

Careers interview: Lao Saal, CEO, SAGA Diagnostics

Surviving an episode of cancer as a teenager set Lao Saal on a path to seek out better ways to detect, monitor and treat the deadly cells. That determination drove him to earn medical and doctoral degrees at Columbia University College of Physicians and Surgeons in New York City in 2008, and in 2016, start SAGA Diagnostics AB, in Lund, Sweden. Serving biopharmaceutical companies as well as healthcare and researchers, SAGA applies ultrasensitive technologies […]

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.